Showing 3581-3590 of 5773 results for "".
- Parexel Enters Agreement with MyEyeDr to Refer Patients into Existing and Future Ophthalmology Clinical Trialshttps://modernod.com/news/parexel-enters-agreement-with-myeyedr-to-refer-patients-into-existing-and-future-ophthalmology-clinical-trials/2481298/Parexel, a clinical research organization (CRO), announced a formal agreement with MyEyeDr to refer its patients into existing and future ophthalmology clinical trials. Terms of the deal were not disclosed. Parexel and MyEyeDr are currently collaborating on recruitme
- Pixium Vision Completes Implantations in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-completes-implantations-in-the-european-pivotal-trial-primavera/2481297/Pixium Vision SA announced the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in geographic atrophy. A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline
- AI-Diagnostics Startup Altris AI Raises $1 Million to Scale AI-Based Eye Care Diagnostics Platformhttps://modernod.com/news/ai-diagnostics-startup-altris-ai-raises-1-million/2481296/Altris AI announced it has raised $1 million to scale its AI-enabled eye care diagnostics solution. Altris AI, which is a US-based startup originally from Ukraine, developed a SaaS platform based on 5 million OCT scans that detected and interpreted more than 100 pathologies an
- Harrow Enters Into Agreement to Acquire Exclusive US Rights to Five Ophthalmic Products from Novartishttps://modernod.com/news/harrow-enters-into-agreement-to-acquire-exclusive-us-rights-to-five-ophthalmic-products-from-novartis/2481292/Harrow announced it has entered into a agreement for the acquisition of the exclusive US commercial rights to five FDA‑approved ophthalmic products from Novartis in a deal worth up to $175 million. This transaction, which is the second acquisition transaction between Har
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar
- Amgen to Buy Horizon Therapeutics in Deal Worth $27.8 Billionhttps://modernod.com/news/amgen-to-buy-horizon-therapeutics-in-deal-worth-278-billion/2481288/Amgen announced it is acquiring rare disease drug company Horizon Therapeutics, maker eye disease drugs Tepezza and Uplizna, in a deal valued at $27.8 billion. The company will pay $116.50 in cash per share, a premium of 19.7% to Horizon’s last closing price. Tepezza (teprotumumab
- Nidek Launches Fully Assisted Refraction System for TS-610https://modernod.com/news/nidek-launches-fully-assisted-refraction-system-for-ts-610/2481287/Nidek has announced the launch of the Fully Assisted Refraction System (FARS), an optional kit for the TS-610 Nidek Tabletop Refraction System. allowing for subjective refractions that integrate the chart and refractor into a single unit. FARS is used to determine th
- Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in MGDhttps://modernod.com/news/azura-ophthalmics-presents-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481286/Azura Ophthalmics announced that positive 3-month efficacy and safety results from its
- CORD Files for Premarket Approval with the FDA for the SC9 IOL for Cataract Surgeryhttps://modernod.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/Cumming Ophthalmic Research and Development (CORD) announced that it has submitted a premarket approval (PMA) application to the FDA for the Model SC9 IOL. The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has over one hundred patents related to IOLs. D
- Lumibird Medical Launches Tango Reflex Neo YAG/SLT Laserhttps://modernod.com/news/lumibird-medical-launches-tango-reflex-neo-yagslt-laser/2481281/Lumibird Medical announced the launch of their next generation YAG/SLT laser, the Tango Reflex Neo, by Ellex. A fully integrated Q-switched Nd:YAG and frequency doubled Nd:YAG laser for anterior-segment YAG and glaucoma indications, Tango Reflex Neo features second-genera